What is HC Wainwright’s Forecast for CTXR Q3 Earnings?

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) – HC Wainwright issued their Q3 2026 earnings estimates for shares of Citius Pharmaceuticals in a research note issued on Monday, May 18th. HC Wainwright analyst S. Ramakanth anticipates that the company will earn ($0.36) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. HC Wainwright also issued estimates for Citius Pharmaceuticals’ Q4 2026 earnings at ($0.25) EPS, Q1 2027 earnings at ($0.28) EPS, Q2 2027 earnings at ($0.20) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.81) EPS.

Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of $0.39 by ($1.34). The firm had revenue of $1.67 million for the quarter, compared to the consensus estimate of $18.79 million.

A number of other analysts also recently issued reports on CTXR. D. Boral Capital reissued a “buy” rating and set a $6.00 target price on shares of Citius Pharmaceuticals in a research report on Wednesday, March 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Citius Pharmaceuticals in a research report on Friday, March 27th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Citius Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $5.00.

Citius Pharmaceuticals Price Performance

NASDAQ CTXR opened at $0.53 on Tuesday. Citius Pharmaceuticals has a 12 month low of $0.48 and a 12 month high of $2.48. The company has a 50-day moving average of $0.78 and a 200-day moving average of $0.91. The company has a market cap of $11.79 million, a P/E ratio of -0.22 and a beta of 1.05.

Institutional Trading of Citius Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Heights Capital Management Inc. acquired a new stake in Citius Pharmaceuticals during the 4th quarter worth approximately $622,000. XTX Topco Ltd increased its position in Citius Pharmaceuticals by 572.8% during the 4th quarter. XTX Topco Ltd now owns 107,118 shares of the company’s stock worth $83,000 after purchasing an additional 91,196 shares in the last quarter. Asset Advisory Group Inc. acquired a new stake in Citius Pharmaceuticals during the 4th quarter worth approximately $46,000. Finally, NewEdge Advisors LLC acquired a new stake in Citius Pharmaceuticals during the 2nd quarter worth approximately $40,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals is a clinical‐stage specialty pharmaceutical company focused on the development and commercialization of critical care products and novel drug delivery systems. Headquartered in Cranford, New Jersey, the company aims to address unmet medical needs in acute care, hospital‐acquired infections and subcutaneous delivery of biologics. Citius operates as a Delaware corporation and trades on the NASDAQ under the symbol CTXR.

One of the company’s leading assets is Mino-Lok, an antibiotic lock solution designed to treat catheter‐related bloodstream infections without catheter removal.